Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.
Steigbigel, Roy T
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. [electronic resource] - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Feb 2010 - 605-12 p. digital
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1537-6591
10.1086/650002 doi
Anti-HIV Agents--adverse effects
CD4 Lymphocyte Count
Double-Blind Method
Drug Resistance, Viral
Drug Therapy, Combination
Female
HIV Infections--drug therapy
HIV-1--drug effects
Humans
Male
Middle Aged
Pyrrolidinones--adverse effects
RNA, Viral--blood
Raltegravir Potassium
Viral Load
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. [electronic resource] - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Feb 2010 - 605-12 p. digital
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1537-6591
10.1086/650002 doi
Anti-HIV Agents--adverse effects
CD4 Lymphocyte Count
Double-Blind Method
Drug Resistance, Viral
Drug Therapy, Combination
Female
HIV Infections--drug therapy
HIV-1--drug effects
Humans
Male
Middle Aged
Pyrrolidinones--adverse effects
RNA, Viral--blood
Raltegravir Potassium
Viral Load